Physician profile
Stephen Eliason
NPI 1700868767
$1,078.00
in general payments reported to CMS, 2019-2025
16 companies · $211 in 2025
The $211 reported for 2025 was more than what 80% of Anatomic Pathology & Clinical Pathology providers received nationally (typical 2025 total: $50.59).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $12.45 · 2021: $13.66 · 2022: $145 · 2023: $443 · 2024: $252 · 2025: $211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $889 · Education: $17.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $888.68 |
| Education | $17.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $182.51 | 2023-2025 | Sucraid, Sucraid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $149.85 | 2020-2025 | Xifaxan |
| Regeneron Healthcare Solutions, INC. | $121.63 | 2022-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $104.17 | 2022-2025 | Entyvio, Eohilia, Gattex |
| Lilly USA, LLC | $91.63 | 2023-2024 | Omvoh |
| Janssen Biotech, INC. | $78.67 | 2023-2024 | Simponi Aria, Simponi, Stelara |
| Organon LLC | $74.99 | 2022-2024 | Hadlima, Renflexis |
| Ardelyx, INC. | $62.59 | 2023-2024 | Ibsrela |
| Braintree Laboratories, INC. | $42.73 | 2024-2025 | Sutab, Suflave |
| Redhill Biopharma INC. | $41.69 | 2022-2023 | Aemcolo, Movantik, Talicia |
| Phathom Pharmaceuticals, INC. | $41.03 | 2024 | Voquezna |
| Alnylam Pharmaceuticals INC. | $21.38 | 2022 | |
| Merck Sharp & Dohme LLC | $20.44 | 2023 | Dificid |
| Celltrion USA INC. | $17.85 | 2024 | Zymfentra |
| Abbvie INC. | $13.66 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $13.18 | 2023 | Linzess |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Eliason listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.